Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00440557 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 375
- Enrollment target
NCT00440557 is a Phase 3 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 375 participants.
The verdict
NCT00440557, a Phase 3 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 375 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that once weekly and once every-2-weeks treatment with epoetin alfa, in patients with anemia associated with chronic kidney disease, is not less effective than the approved treatment with epoetin alfa that is given 3 times weekly with respect to changes in hemoglobin.
Interventions
- DRUG Epoetin alfa 3 times weekly /once weekly
- DRUG Epoetin alfa once weekly
- DRUG Epoetin alfa once every two weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00440557
The ClinicalTrials.gov registry entry for NCT00440557 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Epoetin alfa 3 times weekly /once weekly is the first listed.
NCT00440557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00440557 about?
NCT00440557 is a clinical study titled "An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease". The purpose of this study is to demonstrate that once weekly and once every-2-weeks treatment with epoetin alfa, in patients with anemia associated with chronic kidney disease, is not less effective than the approved treatment with epoetin alfa that is given 3 times weekly with respect to changes in...
What is the current status of trial NCT00440557?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 375 participants. The study started on 2006-09. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00440557?
The interventions under investigation include: Epoetin alfa 3 times weekly /once weekly (DRUG), Epoetin alfa once weekly (DRUG), Epoetin alfa once every two weeks (DRUG).
Who is sponsoring clinical trial NCT00440557?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.